TGFB1 and neoplasm: To further elucidate the functional roles of IL-10 or TGF-β1, exogenous IL-10 or TGF-β1 recombinant proteins were used to treat tumor cells for 12 h, respectively, and then the cell viability was detected at 24 h after CAP treatment.